Drospirenone and estradiol: a new option for the postmenopausal woman

@article{Archer2007DrospirenoneAE,
  title={Drospirenone and estradiol: a new option for the postmenopausal woman},
  author={David F Archer},
  journal={Climacteric},
  year={2007},
  volume={10},
  pages={10 - 3}
}
  • D. Archer
  • Published 1 January 2007
  • Medicine
  • Climacteric
The efficacy of estrogen with or without a progestogen as hormone replacement therapy (HRT) for menopausal symptoms is well-established. Recent large-scale randomized studies with combined estrogen/progestogen therapy (EPT) have raised a number of safety issues, specifically the potential risk for coronary heart disease. Subsequent analyses and other studies have indicated that HRT may be cardioprotective in younger postmenopausal women. A new continuous EPT combines natural 17β-estradiol (E2… 

Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review

All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice for postmenopausal women with vasomotor symptoms.

Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women.

The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms and the frequency of hot flushes was reduced.

What do TSECs provide in the menopausal hormone therapy?

  • P. LlanezaJ. Calaf D. Lubian
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2018
The objective of this guide will be to analyze the efficacy and safety of TSEC consisting of CE/BZA in postmenopausal women.

Progestogen safety and tolerance in hormonal replacement therapy

Short-term clinical studies, observational, and in animal and in vitro studies indicate that both micronized progesterone and dydrogesterone are the safer progestogens with an acceptable metabolic profile.

Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women

The results from this large post-marketing surveillance study confirm the efficacy and safety of DRSP 2 mg/E2 1 mg tablet in Korean postmenopausal women.

One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women

The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women.

Optimal tolerability of ultra-low-dose continuous combined 17β-estradiol and norethisterone acetate: laboratory and safety results

Both ultra-low-dose combinations were neutral to changes in lipid and lipoprotein, hemostasis parameters and carbohydrate metabolism during the trial and had neutral effects on metabolic parameters in the study population.

Hormonal therapy with estradiol and drospirenone improves endothelium-dependent vasodilation in the coronary bed of ovariectomized spontaneously hypertensive rats

  • M. BorgoE. Claudio G. Abreu
  • Medicine, Biology
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • 2016
Hormonal therapy with E2 and DRSP may be an important therapeutic option in the prevention of coronary heart disease in hypertensive post-menopausal women.

References

SHOWING 1-10 OF 30 REFERENCES

Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension

Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women.

Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension

Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.

Added benefits of drospirenone for compliance

  • J. Foidart
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
Significant improvements were observed in quality of life during treatment with 1 mg 17β-estradiol/2 mg drospirenone, which also resulted in higher mean scores than estradiol alone, and that the effect on body weight is dependent on the dose of drospirnone, and this is due to droSpirenone's antimineralocorticoid activity.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.

Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial

The use of drospirenone combined with estradiol provides protection against endometrial hyperplasia, reduces endometrian bleeding with time, and relieves menopausal symptoms.

Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens

It is demonstrated that the combinations of 1, 2, and 3’mg drospirenone with 1 mg estradiol are safe and effective for the treatment of climacteric symptoms.

Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen.

In Europe, a cyclic combined regimen comprising estrogen and 100 mg micronized progesterone administered on days 1-25 has been shown to provide endometrial safety, absence of bleeding and a high rate of tolerability.

Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis

Although endometrial thickness increased slightly, the safety of the endometrium was assured, as no cases of hyperplasia or cancer occurred, and the combination of 17β-estradiol and drospirenone has a positive effect on BMD and a potentially beneficial effect on lipids.

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

Conjugated equine estrogens provided no overall protection against myocardial infarction or coronary death in generally healthy postmenopausal women during a 7-year period of use.